For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Adagene Inc. Sponsored ADR (ADAG) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Adagene Inc. Sponsored ADR is one of 1019 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank gau ...

SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in multiple investor conferences in June 2024. Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide a company update, including progress on the masked, anti-CTLA-4 SAFEbody® ADG126. Company management will also host investor meetings. Jefferie ...

SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in multiple investor conferences in June 2024. Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide a company update, including progress on the masked, anti-CTLA-4 SAFEbody® ADG126. Company management will also host investor meetings. Jefferie ...

Exhibit 1.1 Adagene Inc. American Depositary Shares Each Representing 1.25 Ordinary Shares ($0.0001 par value per Ordinary Share) SALES AGREEMENT March 29, 2024 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12 Floor New York, New York 10019 Ladies and Gentlemen: Adagene Inc., an exempted company incorporated with limited liability under the laws of the Cayman Islands (the "Company"), confirms its agreement (this "Agreement") with Leerink Partners LLC (the "Agent"), as follows: 1. Issuance and Sale of AD ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF ...

- Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer (CRC) with higher, more frequent and repeat dosing of anti-CTLA-4 therapy in combination with anti-PD-1 - - Ongoing combination phase 2 dose expansion in MSS CRC increased to over 50 patients, including initiation of a new, unprecedented 20 mg/kg loading dose regimen, with data anticipated during 2024 - - Validatio ...

- Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy - SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the "SAB"). Dr. Lenz is the Associate Director for Clinical Research an ...

- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and repeat doses of the anti-CTLA-4 therapy - - Preliminary survival analysis of ADG126 10 mg/kg dosing regimens in patients without liver and peritoneal metastases indicates best-in-class median progression-free survival (PFS) of seven months - - Data from additional patients at 10 mg/kg Q3W dosing regimen expecte ...

Exhibit 99.1 Adagene Announces Updates to its Board of Directors SAN DIEGO and SUZHOU, China, April 28, 2023 – Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced updates to its board of directors (the “Board”), including the following: ● Mervyn Turner, Ph.D., is appointed as a director. Dr. Turner accumulated over 25 years of experience at Merck Research Laboratories in ...

公司财务风险 - 公司的财务前景和对额外资本需求的风险包括公司有限的运营历史，可能难以评估当前业务并预测未来表现[19] - 公司可能需要获得大量额外融资来资助增长和运营，这些融资可能无法以可接受的条件获得，甚至根本无法获得[20] - 公司未能遵守与隐私或数据安全相关的现行或未来法律法规可能导致政府执法行动[39] - 全球个人信息和重要数据的监管框架正在迅速发展，对公司的影响可能会持续不确定[40] 中国市场监管风险 - 中国政府对公司经营行为有重大监督，可能随时干预或影响公司运营[32] - 中国监管机构已实施和考虑了许多关于数据保护的立法和监管提案[41] - 中国市场iPhone销售创下收入纪录为967.7亿美元[110] - 中国生物制药行业受到中国政府全面监管，监管框架发生重大变化[60] 法律合规风险 - PCAOB历史上未能检查我们的审计师，导致投资者无法获得检查的好处[33] - PCAOB对位于中国大陆的审计师进行检查的历史限制已在2022年前解除[34] - HFCAA法案将非检查年限从三年减少到两年，导致公司ADS股票可能被禁止在纳斯达克证券交易所交易或被摘牌[36] - 美国通过的Accelerating Holding Foreign Companies Accountable Act法案将影响公司ADS股票在纳斯达克证券交易所交易的时间[37] 公司业务风险 - 公司的产品候选品的临床开发风险包括可能无法识别或发现新的产品候选品，可能将有限资源用于追求某个产品候选品并未能充分利用后来可能证明更有利润或更有成功可能性的产品候选品[21] - 公司历史上出现净亏损，未来可能继续出现净亏损[83] - 公司自2011年成立以来，主要通过许可和合作交易产生收入，但至今尚未通过商业产品销售产生任何收入[84] - 公司的研究项目可能最终无法产生临床开发的潜在产品候选者[93] 产品研发风险 - 公司的产品候选者依赖于专有的抗体发现平台，但目前尚未在任何司法管辖区批准基于这些技术的产品[97] - 公司的产品候选者可能面临比预期更早的竞争[99] - 临床试验可能会失败，公司无法保证产品候选药物的成功[104] - 临床试验可能会因多种原因延迟、暂停或终止，包括监管授权延迟、招募患者困难、安全性或耐受性问题等[108]